March 20 (Reuters) - GlaxoSmithKline’s HIV treatments division said on Friday that Canada’s healthcare regulator has approved its long-acting HIV injection, in a major win for the British drugmaker after a U.S. rejection late last year.
GSK's ViiV Healthcare said that Health Canada had given the green light to Cabenuva, a monthly injection to suppress the virus that causes AIDS and is aimed as an alternative to daily pills. (bit.ly/3aatmo8)
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Vinay Dwivedi)
Openly is an initiative of the Thomson Reuters Foundation dedicated to impartial coverage of LGBT+ issues from around the world.
Our Standards: The Thomson Reuters Trust Principles.